Literature DB >> 11133768

Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma.

B F Skinnider1, A J Elia, R D Gascoyne, L H Trümper, F von Bonin, U Kapp, B Patterson, B E Snow, T W Mak.   

Abstract

Hodgkin lymphoma (HL) is characterized by the abnormal expression of multiple cytokines, accounting for its unique clinicopathologic features. We have previously shown that interleukin-13 (IL-13) is secreted by HL cell lines and may serve as an autocrine growth factor. To determine the frequency of IL-13 expression in lymphoma patients, tissue sections from 36 patients with classical HL, 5 patients with nodular lymphocyte predominance HL (NLPHL), and 23 patients with non-Hodgkin lymphoma (NHL) were subjected to in situ hybridization. In 31 of 36 cases (86%) of classical HL patients of all histologic subtypes, between 25% to almost 100% of Hodgkin and Reed Sternberg (HRS) cells were positive for IL-13 expression. In contrast, in no case of NLPHL and in only 4 of 23 NHL cases (1 of 5 T-cell-rich B-cell lymphomas, 2 of 5 anaplastic large cell lymphomas, and 1 of 5 peripheral T-cell lymphomas) did the neoplastic cells express IL-13. The expression of the IL-13 receptor chain alpha1 (IL-13Ralpha1) was also analyzed by in situ hybridization. In 24 of 27 (89%) cases of classical HL, between 25% to 75% of HRS cells, as well as a high frequency of lymphocytes and histiocytes, were positive for IL-13Ralpha1 expression. These results were confirmed by the construction of complementary DNA libraries from single HRS cells, followed by polymerase chain reaction analysis, in which IL-13Ralpha1 transcripts were found to be present in all 6 cases of HL. These data indicate that expression of IL-13 and IL-13Ralpha1 is a common feature of HRS cells in HL, consistent with the hypothesis that IL-13 may play a role in autocrine growth in classical HL.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11133768     DOI: 10.1182/blood.v97.1.250

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  37 in total

Review 1.  Immunotherapy targeting EBV-expressing lymphoproliferative diseases.

Authors:  Catherine M Bollard; Laurence J Cooper; Helen E Heslop
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

2.  Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress.

Authors:  Kathrin Zaugg; Yi Yao; Patrick T Reilly; Karuppiah Kannan; Reza Kiarash; Jacqueline Mason; Ping Huang; Suzanne K Sawyer; Benjamin Fuerth; Brandon Faubert; Tuula Kalliomäki; Andrew Elia; Xunyi Luo; Vincent Nadeem; David Bungard; Sireesha Yalavarthi; Joseph D Growney; Andrew Wakeham; Yasmin Moolani; Jennifer Silvester; Annick You Ten; Walbert Bakker; Katsuya Tsuchihara; Shelley L Berger; Richard P Hill; Russell G Jones; Ming Tsao; Murray O Robinson; Craig B Thompson; Guohua Pan; Tak W Mak
Journal:  Genes Dev       Date:  2011-05-15       Impact factor: 11.361

3.  Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation.

Authors:  Larisa J Geskin; Sara Viragova; Donna B Stolz; Patrizia Fuschiotti
Journal:  Blood       Date:  2015-01-27       Impact factor: 22.113

4.  CD137 signaling in Hodgkin and Reed-Sternberg cell lines induces IL-13 secretion, immune deviation and enhanced growth.

Authors:  Sakthi Rajendran; Weng Tong Ho; Herbert Schwarz
Journal:  Oncoimmunology       Date:  2016-04-29       Impact factor: 8.110

5.  Identification of BERP (brain-expressed RING finger protein) as a p53 target gene that modulates seizure susceptibility through interacting with GABA(A) receptors.

Authors:  Carol C Cheung; Caimei Yang; Thorsten Berger; Kathrin Zaugg; Patrick Reilly; Andrew J Elia; Andrew Wakeham; Annick You-Ten; Ning Chang; Lijun Li; Qi Wan; Tak Wah Mak
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-11       Impact factor: 11.205

Review 6.  The biology of human lymphoid malignancies revealed by gene expression profiling.

Authors:  Louis M Staudt; Sandeep Dave
Journal:  Adv Immunol       Date:  2005       Impact factor: 3.543

Review 7.  The role of NKT cells in tumor immunity.

Authors:  Masaki Terabe; Jay A Berzofsky
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

Review 8.  Relapsed and refractory Hodgkin lymphoma: transplantation strategies and novel therapeutic options.

Authors:  Kevin A David; Lauren Mauro; Andrew M Evens
Journal:  Curr Treat Options Oncol       Date:  2007-10

9.  Prognostic significance of new immunohistochemical markers in refractory classical Hodgkin lymphoma: a study of 59 cases.

Authors:  Danielle Canioni; Bénédicte Deau-Fischer; Pierre Taupin; Vincent Ribrag; Richard Delarue; Jacques Bosq; Marie-Thérèse Rubio; Damien Roux; Viorel Vasiliu; Bruno Varet; Nicole Brousse; Olivier Hermine
Journal:  PLoS One       Date:  2009-07-22       Impact factor: 3.240

10.  Inflammation and tissue repair markers distinguish the nodular sclerosis and mixed cellularity subtypes of classical Hodgkin's lymphoma.

Authors:  A Birgersdotter; K R N Baumforth; A Porwit; J Sjöberg; W Wei; M Björkholm; P G Murray; I Ernberg
Journal:  Br J Cancer       Date:  2009-09-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.